Skip to main content

Hereditary Hemorrhagic Telangiectasia

2
Pipeline Programs
7
Companies
4
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
1
0
0
1
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

7 companies ranked by most advanced pipeline stage

Baxter
BaxterCosta Rica - Cartago
1 program
1
Tranexamic acid first, than placeboPhase 31 trial
Active Trials
NCT01031992Completed23Est. Oct 2002
Diagonal Therapeutics
Diagonal TherapeuticsMA - Watertown
1 program
1
DIAG723Phase 1/21 trial
Active Trials
NCT07623525Not Yet Recruiting93Est. Dec 2027
Colorado Therapeutics
Colorado TherapeuticsCO - Louisville
1 program
Comprehensive HHT Outcomes Registry of the United States (CHORUS)N/A
Oregon Therapeutics
Oregon TherapeuticsFrance - Paris
1 program
Comprehensive HHT Outcomes Registry of the United States (CHORUS)N/A1 trial
Active Trials
NCT06259292Recruiting10,000Est. Nov 2033
Angeles Therapeutics
Angeles TherapeuticsCA - Los Angeles
1 program
Comprehensive HHT Outcomes Registry of the United States (CHORUS)N/A
HELP Therapeutics
HELP TherapeuticsChina - Nanjing
1 program
Nationwide Awareness Campaign and Call for Dental Screening for HHT in GermanyN/A1 trial
Active Trials
NCT03549949UnknownEst. Jul 2022
Baxter International
1 program
Tranexamic acid first, than placeboPHASE_3

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
BaxterTranexamic acid first, than placebo
Diagonal TherapeuticsDIAG723
Oregon TherapeuticsComprehensive HHT Outcomes Registry of the United States (CHORUS)
HELP TherapeuticsNationwide Awareness Campaign and Call for Dental Screening for HHT in Germany

Clinical Trials (4)

Total enrollment: 10,116 patients across 4 trials

NCT01031992BaxterTranexamic acid first, than placebo

Tranexamic Acid and Epistaxis in Hereditary Hemorrhagic Telangiectasia (HHT)

Start: Mar 2002Est. completion: Oct 200223 patients
Phase 3Completed
NCT07623525Diagonal TherapeuticsDIAG723

DIAG723 in Adults With Hereditary Hemorrhagic Telangiectasia

Start: Jun 2026Est. completion: Dec 202793 patients
Phase 1/2Not Yet Recruiting
NCT06259292Oregon TherapeuticsComprehensive HHT Outcomes Registry of the United States (CHORUS)

Comprehensive HHT Outcomes Registry of the United States (CHORUS)

Start: Nov 2023Est. completion: Nov 203310,000 patients
N/ARecruiting
NCT03549949HELP TherapeuticsNationwide Awareness Campaign and Call for Dental Screening for HHT in Germany

Nationwide Awareness Campaign and Call for Dental Screening for HHT in Germany

Start: Jun 2018Est. completion: Jul 2022
N/AUnknown

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 late-stage (Phase 3) programs, potential near-term approvals
1 actively recruiting trials targeting 10,116 patients
7 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.